Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

AYA STEPS RCT: AYA Self-Management Via Texting, Education & Plans for Survivors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03363711
Recruitment Status : Suspended (Covid-19)
First Posted : December 6, 2017
Last Update Posted : April 24, 2020
Sponsor:
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

Brief Summary:

The proposed project will leverage two programs of research at UPenn and CHOP that are delivering technology-based interventions to adolescent and young adult (AYA) cancer survivors.

In the proposed study, all AYA survivors will receive a care plan via a tool (Smart-ALACC). They will then be randomized to receive (or not) a mobile health application (AYA STEPS) that will provide tailored messages to enhance uptake of their care plan.


Condition or disease Intervention/treatment
Adolescent and Young Adult (AYA) Cancer Survivors Other: AYA STEPS

Layout table for study information
Study Type : Observational
Actual Enrollment : 25 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: AYA STEPS RCT: AYA Self-Management Via Texting, Education & Plans for Survivors
Actual Study Start Date : March 1, 2017
Actual Primary Completion Date : December 1, 2019
Estimated Study Completion Date : December 1, 2020

Intervention Details:
  • Other: AYA STEPS
    a mobile health application


Primary Outcome Measures :
  1. Number of Completed mobile data and questionnaires [ Time Frame: 10 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years to 29 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
15-29 year olds with a history of malignant cancer diagnosis.
Criteria

Inclusion Criteria:

  • AYA is 15-29 year old with a history of a malignant cancer diagnosis;
  • Completed cancer treatment and are currently in remission or receiving cancer survivorship care;
  • Seen for follow-up oncology care at CHOP or Penn;
  • For AYA less than 18 years old, must have a caregiver to provide informed consent.

Exclusion Criteria:

  • Cognitive impairments that would limit AYA ability to independently care for health as determined by the medical team.
  • Absence of the inclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03363711


Locations
Layout table for location information
United States, Pennsylvania
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Abramson Cancer Center of the University of Pennsylvania
Investigators
Layout table for investigator information
Principal Investigator: Christine Hill-Kayser, MD Abramson Cancer Center of the University of Pennsylvania
Layout table for additonal information
Responsible Party: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier: NCT03363711    
Other Study ID Numbers: UPCC 26916
First Posted: December 6, 2017    Key Record Dates
Last Update Posted: April 24, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No